BCM
ABBV icon

Bluefin Capital Management’s AbbVie ABBV Stock Holding History

Bluefin Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-10,000
Closed -$5K – 386
2020
Q1 		$5K Buy
+10,000
New +$852K ﹤0.01% 391
2019
Q2 		– Sell
-14,000
Closed -$21K – 330
2019
Q1 		$21K Buy
+14,000
New +$1.15M ﹤0.01% 328

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bluefin Capital Management's ABBV Position: Q4 2023 in Review

Bluefin Capital Management sold out of AbbVie (ABBV) in Q4 2023, closing a stake of 1,500 shares — an estimated $224K sold.

Bluefin Capital Management first reported a position in ABBV in Q2 2013 and held it in 28 quarters. The position peaked at $13.5M in Q1 2020. 3,323 funds tracked by Wall St. Rank hold ABBV as of Q4 2023.

  • Bluefin Capital Management reported no remaining AbbVie position as of Q4 2023 after selling out during the quarter.
  • Bluefin Capital Management sold 1,500 AbbVie shares in Q4 2023, an estimated $224K.
  • Bluefin Capital Management first reported a position in AbbVie in Q2 2013 and held it in 28 quarters.
  • Bluefin Capital Management's AbbVie position peaked at $13.5M in Q1 2020.
  • 3,323 funds tracked by Wall St. Rank held AbbVie as of Q4 2023.

Based on Bluefin Capital Management's 13F filing for Q4 2023, filed 16 Feb 2024.